Letter to the Editor| Volume 364, ISSUE 4, P505-507, October 2022

IgD multiple myeloma: The relevant clinical role of laboratory in the detection of rare plasma cell neoplasms

      To the Editor,
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of the Medical Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Selene II
        • Jose JA
        • Khalil MJ
        • Faisal MS
        • Malik MN.
        Presentation patterns, diagnostic markers, management strategies, and outcomes of IgD multiple myeloma: a systematic review of literature.
        Cureus. 2019; 11: e4011
        • Righetti G
        • Graziani MS.
        Sei casi di gammopatia monoclonale IgD.
        Biochim Clin. 2011; 35: 417
        • Lake Littlejohn C
        • Whiteley A
        • Stone MJ.
        Early stage IgD multiple myeloma in a 50-year-old man.
        Proc (Bayl Univ Med Cent). 2019; 33: 263-265
        • Chen L
        • Fan F
        • Deng J
        • Xu J
        • Xu A
        • Sun C
        • Hu Y.
        Clinical characteristics and prognosis of immunoglobulin D myeloma in the novel agent era.
        Ann Hematol. 2019; 98: 963-970
        • Rajkumar SV.
        Updated Diagnostic criteria and staging system for multiple myeloma.
        Am Soc Clin Oncol Educ Book. 2016; 35: e418-e423